Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Roy Chemaly, MD PhD, Michael Boeckh, MD, Karin Weber, Roman Fleischhackl, Marita Stevens, Bart Michiels, David Rivas, Jason Chien, James Witek

Blood (2019) 134 (Supplement_1): 4478.

https://doi.org/10.1182/blood-2019-130423

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Lamictal® and Hemophagocytic Lymphohistiocytosis (HLH)

Ibrahim Tora, MD, Logan Rhea, DO, Margaret Holbrook, Physician Assistant, William Ershler, MD, Yemsrach Gami, MD

Blood (2019) 134 (Supplement_1): 4880.

https://doi.org/10.1182/blood-2019-127531

Published: 2019

Journal Articles

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

Catherine Diefenbach, MD, Fangxin Hong, PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H. Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Brad S Kahl, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 679.

https://doi.org/10.1182/blood-2018-99-115390

Published: 2018

Journal Articles

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Blood (2018) 132 (Supplement 1): 683.

https://doi.org/10.1182/blood-2018-99-115241

Published: 2018

Journal Articles

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Carmen Martinez, MD PhD, Cecilia Carpio, MD, Inmaculada Heras, Eduardo Ríos Herranz, MD, Joan Buch, Antonio Gutierrez, MD PhD, Samuel Romero, Izaskun Ceberio, Irene Garcia-Garcia, Antonia Rodriguez Izquierdo, PhD, Rosalia Alonso, Joan Bargay, MD PhD, Cristina Barrenetxea Lekue, PhD, Narvaez Javier, Manuel Espeso de Haro, MD, Luis Palomera, MD PhD, Ramon García-Sanz, MD PhD

Blood (2018) 132 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2018-99-115774

Published: 2018

Journal Articles

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Eric D Jacobsen, MD, Won-Seog Kim, MD PhD, Francine M. Foss, MD, Ranjana H. Advani, MD, Jose Maria Roncero Vidal, MD, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, PhD, Raquel De Ona Navarrete, MD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Rufino Mondejar, PhD, Miguel A. Piris, PhD MD, Robert Curry, BA, MBA, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2018) 132 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2018-99-116277

Published: 2018

Journal Articles

Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting

Peter Martin, MD, Paul Barr, MD, Brad S. Kahl, MD, Ashutosh Pathak

Blood (2016) 128 (22): 5591.

https://doi.org/10.1182/blood.V128.22.5591.5591

Published: 2016

Journal Articles

Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131

Karen R. Rabin, MD PhD, Johann Hitzler, MD FRCP (C), FAAP, Vilmarie Rodriguez, MD, Reuven Schore, MD, Anne Angiolillo, MD, Michael J. Burke, MD, Wanda Salzer, MD, Kelly Maloney, MD, Xiaomin Lu, PhD, Meenakshi Devidas, PhD, Mignon L. Loh, MD, Elizabeth Raetz, MD, Stephen P Hunger, MD

Blood (2015) 126 (23): 2502.

https://doi.org/10.1182/blood.V126.23.2502.2502

Published: 2015

Journal Articles

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Sven de Vos, MD PhD, Lode Swinnen, MD, Mark Kozloff, MD, Ding Wang, MD PhD, Erin Reid, MD, Loretta Nastoupil, MD, Nathan Fowler, MD, Jaclyn Cordero, Diane D'Amico, Susan Diehl, Martin Dunbar, DrPH, Ming Zhu, PhD, Shekman Wong, PhD, Sari Heitner Enschede, MD, David Chien, MD, Rod A. Humerickhouse, MD PhD, Christopher Flowers, MD

Blood (2015) 126 (23): 255.

https://doi.org/10.1182/blood.V126.23.255.255

Published: 2015

Journal Articles

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Bradley M. Haverkos, MD MPH, Katie Cortright, BS, Leslie A. Andritsos, MD, William Blum, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Steven M. Devine, MD, Samantha M. Jaglowski, MD MPH

Blood (2014) 124 (21): 1168.

https://doi.org/10.1182/blood.V124.21.1168.1168

Published: 2014

Journal Articles

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Lilia Weiss, MD, Dianna Gary, BSN, RN, Arlene S. Swern, PhD, John Freeman, MD, Mary M. Sugrue, MD, PhD

Blood (2013) 122 (21): 2975.

https://doi.org/10.1182/blood.V122.21.2975.2975

Published: 2013

Journal Articles

Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis

Omer Iqbal, MD, Daneyal Syed, Michael Mosier, MD, Julia Malalis, Christine Mata, Amy Lin, Nicole Mitchel, Schurahazard Abro, Debra Hoppensteadt, Ph.D., Jawed Fareed, Ph.D., Charles Bouchard

Blood (2013) 122 (21): 1117.

https://doi.org/10.1182/blood.V122.21.1117.1117

Published: 2013

Journal Articles

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Matthew A Lunning, DO, Jason Gonsky, MD, PhD, Jia Ruan, MD, PhD, Adrienne A. Phillips, MD, MPH, Melissa Pulitzer, MD, Alison Moskowitz, MD, Christiane Querfeld, MD PhD, Patricia L Myskowski, M.D., Ariela Noy, MD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 2735.

https://doi.org/10.1182/blood.V120.21.2735.2735

Published: 2012

Journal Articles

Hemophagocytic Lymphohistiocytosis in Adults: A Case Series of 30 Patients At a U.S. Tertiary Care Center

Sarah A. Buckley, MD, Daniel Egan, MD, Roland B. Walter, MD, PhD

Blood (2012) 120 (21): 4681.

https://doi.org/10.1182/blood.V120.21.4681.4681

Published: 2012

Journal Articles

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Blood (2011) 118 (21): 777.

https://doi.org/10.1182/blood.V118.21.777.777

Published: 2011

Journal Articles

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Aziz Nazha, Farhad Ravandi, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Marina Konopleva, M.D., Ph.D., Jorge E. Cortes, Alessandra Ferrajoli, MD, Steven M. Kornblau, Michael Andreeff, M.D., Ph.D., Min Du, Mark Brandt, BS, Stefan Faderl, MD

Blood (2011) 118 (21): 1550.

https://doi.org/10.1182/blood.V118.21.1550.1550

Published: 2011

Journal Articles

Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL)

Blood (2010) 116 (21): 285.

https://doi.org/10.1182/blood.V116.21.285.285

Published: 2010

Journal Articles

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Blood (2009) 114 (22): 1706.

https://doi.org/10.1182/blood.V114.22.1706.1706

Published: 2009

Journal Articles

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Cara C Tigue, BA, Dennis P West, PhD, Dennis W Raisch, PhD, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Athena T Samaras, BA, Paul Bennett, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4662.

https://doi.org/10.1182/blood.V112.11.4662.4662

Published: 2008

NARROW

Freesia Study Design: JNJ-53718678 in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Lamictal® and Hemophagocytic Lymphohistiocytosis (HLH)

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting

Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis

Pralatrexate in Relapsed/Refractory HTLV-1 Associated Adult T-Cell Lymphoma/Leukemia: A New York City Multi-Institutional Experience.

Hemophagocytic Lymphohistiocytosis in Adults: A Case Series of 30 Patients At a U.S. Tertiary Care Center

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL)

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only